MX2007009059A - Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos. - Google Patents

Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos.

Info

Publication number
MX2007009059A
MX2007009059A MX2007009059A MX2007009059A MX2007009059A MX 2007009059 A MX2007009059 A MX 2007009059A MX 2007009059 A MX2007009059 A MX 2007009059A MX 2007009059 A MX2007009059 A MX 2007009059A MX 2007009059 A MX2007009059 A MX 2007009059A
Authority
MX
Mexico
Prior art keywords
antibiotic
factors
compositions
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
MX2007009059A
Other languages
English (en)
Inventor
Ameriga Lazzarini
Luciano Gastaldo
Gianpaolo Candiani
Ismaela Ciciliato
Daniele Losi
Flavia Marinelli
Enrico Selva
Franco Parenti
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of MX2007009059A publication Critical patent/MX2007009059A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invencion se refiere a una sustancia antibiotica de origen microbiano denominada arbitrariamente antibiotico 107891, la cual se produce por fermentacion de Microbispora sp. ATCC PTA-5024, sales y composiciones farmaceuticamente aceptables de la misma y su uso como agente antibacteriano teniendo actividad inhibidora frente a microbios susceptibles. El antibiotico 107891, el cual es un complejo que comprende dos Factores denominados Factores A1 y A2, tiene una estructura peptidica que contiene lantionina y metillantionina como constituyentes que son caracteristicas tipicas de los antibioticos del grupo lantibioticos. El antibiotico 107891 y sus Factores A1 y A2 muestran una buena actividad antibacteriana frente a bacterias Gram-positivas, incluyendo cepas resistentes a metilcilina y a vancomicina, y tambien son activos frente a algunas bacterias Gram-negativas como por ejemplo M. catharralis, la especie Neisseria y H. influenzae y Micobacteria.
MX2007009059A 2005-01-26 2005-01-27 Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos. MX2007009059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/045,628 US7351687B2 (en) 2003-07-18 2005-01-26 Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
PCT/US2005/002733 WO2006080920A1 (en) 2005-01-26 2005-01-27 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof

Publications (1)

Publication Number Publication Date
MX2007009059A true MX2007009059A (es) 2008-02-12

Family

ID=36740829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007009059A MX2007009059A (es) 2005-01-26 2005-01-27 Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos.

Country Status (26)

Country Link
US (1) US7351687B2 (es)
EP (2) EP2402366A1 (es)
JP (1) JP4191238B2 (es)
KR (1) KR100896826B1 (es)
CN (1) CN101189252B (es)
AU (1) AU2005326149C1 (es)
BR (1) BRPI0519942A2 (es)
CA (1) CA2593801A1 (es)
CY (1) CY1113030T1 (es)
DK (1) DK1848731T3 (es)
EA (1) EA016608B1 (es)
ES (1) ES2387557T3 (es)
HR (1) HRP20120634T1 (es)
IL (1) IL184377A0 (es)
MA (1) MA29237B1 (es)
MX (1) MX2007009059A (es)
NO (1) NO20073490L (es)
NZ (1) NZ556368A (es)
PL (1) PL1848731T3 (es)
PT (1) PT1848731E (es)
RS (1) RS52427B (es)
SI (1) SI1848731T1 (es)
TN (1) TNSN07286A1 (es)
UA (1) UA87548C2 (es)
WO (1) WO2006080920A1 (es)
ZA (1) ZA200705495B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
CA2749278A1 (en) 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59198982A (ja) 1983-04-28 1984-11-10 Meiji Seika Kaisha Ltd 新抗生物質ｓｆ−２２４０物質およびその製造法
EP0592835A3 (en) 1992-09-23 1995-03-15 Bristol Myers Squibb Co Antibiotics of type BU-4803T.
US6551591B1 (en) 2001-09-07 2003-04-22 Essential Therapeutics, Inc. Antibiotics from microbispora
US6551581B1 (en) 2001-12-27 2003-04-22 Avon Products, Inc. Methods for improving the aesthetic appearance of skin and hair
ES2281808T3 (es) * 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
WO2006075988A1 (en) * 2005-01-12 2006-07-20 Vicuron Pharmaceuticals Inc. Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof
RS52513B (en) * 2005-01-12 2013-04-30 Sentinella Pharmaceuticals Inc. ("Sentinella") ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE
UA87546C2 (ru) * 2005-01-12 2009-07-27 Найконс С.К.А.Р.Л Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли, композиция и их использование

Also Published As

Publication number Publication date
EP1848731A4 (en) 2008-11-12
EP1848731A1 (en) 2007-10-31
EP2402366A1 (en) 2012-01-04
CN101189252A (zh) 2008-05-28
NZ556368A (en) 2010-09-30
AU2005326149A1 (en) 2006-08-03
HRP20120634T1 (hr) 2012-08-31
CA2593801A1 (en) 2006-08-03
UA87548C2 (ru) 2009-07-27
SI1848731T1 (sl) 2012-09-28
NO20073490L (no) 2007-08-07
EA200701384A1 (ru) 2008-02-28
IL184377A0 (en) 2007-10-31
CN101189252B (zh) 2012-07-18
EP1848731B1 (en) 2012-05-23
PT1848731E (pt) 2012-08-20
US20050233952A1 (en) 2005-10-20
RS52427B (en) 2013-02-28
AU2005326149B2 (en) 2009-10-29
US7351687B2 (en) 2008-04-01
EA016608B1 (ru) 2012-06-29
CY1113030T1 (el) 2016-04-13
MA29237B1 (fr) 2008-02-01
TNSN07286A1 (fr) 2008-12-31
DK1848731T3 (da) 2012-09-03
KR100896826B1 (ko) 2009-05-12
PL1848731T3 (pl) 2012-10-31
KR20070090043A (ko) 2007-09-04
AU2005326149C1 (en) 2010-04-01
ZA200705495B (en) 2008-12-31
ES2387557T3 (es) 2012-09-26
JP4191238B2 (ja) 2008-12-03
JP2008528581A (ja) 2008-07-31
BRPI0519942A2 (pt) 2009-04-07
WO2006080920A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
MX2007009059A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos.
Dosler et al. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms
Morris et al. Evaluation of bacteriophage anti-biofilm activity for potential control of orthopedic implant-related infections caused by Staphylococcus aureus
TW200510541A (en) Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
Giamarellou et al. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa
WO2006065977A3 (en) Antimicrobial peptides and methods of use
Ding et al. Isolation and identification of lipopeptide antibiotics from Paenibacillus elgii B69 with inhibitory activity against methicillin-resistant Staphylococcus aureus
Huang et al. Isolation and partial characterization of cyclic lipopeptide antibiotics produced by Paenibacillus ehimensis B7
JP2012513467A5 (es)
Kelman et al. Chemical warfare in the sea: The search for antibiotics from Red Sea corals and sponges
Fan et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria
Gómez-Garcés et al. In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria
Kádár et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains
Bell et al. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)
Giacometti et al. In vitro activity and killing effect of the synthetic hybrid cecropin A–melittin peptide CA (1–7) M (2–9) NH2 on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics
Qi et al. Pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and-resistant Enterococci in vitro and in vivo of a galleria mellonella larval infection model
UA87546C2 (ru) Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли, композиция и их использование
EA200701267A1 (ru) Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли и композиции и их применение
Ulm et al. Targeting bactoprenol-coupled cell envelope precursors
Williams et al. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Oli et al. Actinomycetes in Medical and Pharmaceutical Industries
Mar Soe et al. Ethyl gallate as a combination drug can overcome resistance in MRSA
KR101970656B1 (ko) 신규한 스트렙토마이시스 리노마이시니 ds620 균주 및 이의 추출물을 포함하는 항균 조성물
Arooj et al. Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens
Lertcanawanichakul et al. Bacteriocin-like protein produced Brevibacillus laterosporus that can inhibit the growth of drug resistant bacteria

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
GB Transfer or rights